|
Powered by Cell Signaling Technology |
|
Powered by Cell Signaling Technology |
| Site Information |
|---|
| AMBIGUOUS SITES: ognl.NoConversionPossible: , ognl.NoConversionPossible: , ognl.NoConversionPossible: , ognl.NoConversionPossible: , ognl.NoConversionPossible: , ognl.NoConversionPossible: , ognl.NoConversionPossible: , ognl.NoConversionPossible: , ognl.NoConversionPossible: , ognl.NoConversionPossible: , ognl.NoConversionPossible: , ognl.NoConversionPossible: , ognl.NoConversionPossible: , ognl.NoConversionPossible: , ognl.NoConversionPossible: , ognl.NoConversionPossible: , ognl.NoConversionPossible: , ognl.NoConversionPossible: , ognl.NoConversionPossible: |
| DSSDSSDsSNSSDSS SwissProt Entrez-Gene |
| Blast this site against: NCBI SwissProt PDB |
| Site Group ID: 25289928 |
| In vivo Characterization | |
|---|---|
| Methods used to characterize site in vivo: | |
| Relevant cell line - cell type - tissue: | |
| References | |
|---|---|
|
Possemato A (2007) CST Curation Set: 2386; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info |
Developed with grants from
|
and literature mining with Linguamatics
|
PhosphoSite, created by Cell Signaling Technology is licensed under a Creative
Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.
|
©2003-2019 Cell Signaling Technology, Inc.
